Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
Montreal, QC, CA, May 11, 2017 – Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced positive data from its Phase 2 NODE-1 trial evaluating etripamil, a novel, potent, fast-acting and short-acting calcium channel blocker in development for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a potentially debilitating cardiac arrhythmia. The data were presented in a late breaking oral presentation at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions in Chicago. The results from the Phase 2 NODE-1 trial show that etripamil demonstrated statistically significant efficacy compared to placebo for the acute termination of PSVT induced in an electrophysiology laboratory.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.